Zealand Pharma AS
(HAM:22Z)
€
38.4
+0.73 (+1.94%)
Market Cap: 2.76 Bil
Enterprise Value: 882.54 Mil
PE Ratio: 3.35
PB Ratio: 1.46
GF Score: 68/100 Zealand Pharma A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 01:40PM GMT
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good morning, everyone, and welcome to the 9:40 session on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharma names here at the firm. It's my great pleasure to be hosting Zealand Pharma in a fireside chat discussion today. And with us is Emmanuel Dulac, who is CEO of the company; and Matt Dallas, CFO of the company as well. And so with that, Emmanuel and Matt, welcome.
Matthew Donald Dallas;S;Senior VP;CFO
Zealand Pharma A
/-&
Thanks, Graig.
Emmanuel Dulac;S;CEO;President
Zealand Pharma A
/-&
Thank you, Graig.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot